Navigating ADME Complexity with High-Fidelity Metabolic Enzymes for Drug-Drug Interaction and Pharmacogenomics Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CYP3A4-mediated metabolism studies. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Recombinant Enzyme | CYP3A4 Holoenzyme + POR Complex Co-expressed oxidoreductase, Heme-incorporated, High Purity (>95%), Sequence Verified. |
View CYP3A4 Products |
| Polymorphism Panel | CYP3A4 Variant Library (*1B, *2, *3, *22, *14, *7) For pharmacogenomics screening and personalized medicine. Includes rare alleles (e.g., rs12721634, rs56324128). |
View CYP3A4 Products |
| Detection Antibody | Anti-CYP3A4 Recombinant Rabbit mAb For Western Blot and IHC, Sequence Verified, Cross-reactivity tested vs CYP3A5 (<5%). |
View CYP3A4 Products |
| Gene Delivery | CYP3A4 Promise-ORF Lentivirus For stable expression in hepatocyte cell lines, induction studies. |
View CYP3A4 Products |
| Validator | CYP3A4 siRNA Set For knockdown verification in hepatocyte models. |
View CYP3A4 Products |
| Antigen / Mutant Protein | CYP3A4 Recombinant / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence verified wild-type and variant panels. |
View CYP3A4 Products |
| Related Target: CYP2D6 | CYP2D6 Enzyme & Variants Parallel DDI pathway, major metabolic enzyme for ~25% of drugs. |
View CYP2D6 Products |
| Related Target: PXR | PXR (NR1I2) Reporter System Nuclear receptor regulating CYP3A4 transcriptional induction. |
View PXR Products |
| Related Target: CYP2C9 | CYP2C9 Variants (*2, *3) Critical for warfarin metabolism and DDI studies. |
View CYP2C9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Activity Coupling Efficiency | Pre-complexed with POR (Cytochrome P450 Oxidoreductase), Heme-saturated (>0.9 heme/protein ratio), Theoretical MW verified by LC-MS. |
| Polymorphism Impact Assessment | Major variant panel (*1B, *2, *3, *22, *14, *7) with confirmed SNP incorporation, Sequence Verified. |
| Isoform Specificity (vs CYP3A5) | High-specificity antibody with <5% cross-reactivity to CYP3A5, Endotoxin Controlled (<1 EU/µg). |
| Induction Screening | Compatible with PXR reporter assays and primary hepatocyte models. |
| Lack of Robust Expression Controls | Sequence Verified Recombinant Benchmark Antibodies included. |
| False Positives in Knockdown Studies | Validated siRNA included for strict specificity checks. |
Live CYP3A4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active DDI Clinical Trials
- ➤ Latest Pharmacogenomics Research
- ➤ Time-Dependent Inhibition Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The regulatory landscape for drug-drug interactions (DDI) is intensifying, with FDA and EMA guidelines increasingly requiring comprehensive CYP3A4 inhibition and induction data prior to IND filing. CYP3A4 metabolizes over 50% of all marketed drugs, making it the most critical enzyme in global drug discovery. As biologics and complex modalities (ADCs, multispecifics) enter the pipeline, understanding their metabolism via CYP3A4 becomes critical for prediction of exposure and safety. The next wave of R&D focuses on pharmacogenomic-guided dosing, utilizing CYP3A4 polymorphism data to predict patient variability, and hepatic organ-on-chip models requiring standardized, high-activity enzyme preparations. Additionally, PK enhancers (e.g., cobicistat, ritonavir) exploit CYP3A4 inhibition to extend drug half-life, while prodrug strategies leverage hepatic CYP3A4 for targeted activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Context / Players | Key Applications / Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Pharma DDI Screening (Pfizer, Novartis) | Reversible & TDI assessment; Pan-Oncology, Cardio | High-activity holoenzyme with POR for accurate IC50 determination |
| Pharmacogenomics Panels | Precision Medicine | Patient stratification | Sequence-verified polymorphic variants (*1B, *2, *3, *22, *14, *7) |
| Biologic ADCs | Oncology | Metabolic stability of payload | CYP3A4-mediated payload metabolism screening |
| Herbal/Natural Products | Alternative Medicine | Induction screening | Induction assays with PXR reporter and CYP3A4 expression systems |
| PK Enhancers | Gilead, AbbVie | HIV, Virology | Inhibition assays (need reliable recombinant enzyme) |
| Prodrugs | AstraZeneca | Solid Tumors | Activation profiling (need native-conformation enzyme) |